Kenza Health Hub logoGet Started
1 May 2026Oral drugsSource update: January 2024

Lactulose Oral: Dosing and Precautions

Lactulose guidance for prevention of constipation in patients taking opioid analgesics, with stool-response monitoring.

Also searched as

Lactulose

Source reviewed

January 2024

Guide category

Oral drugs

Safety boundary

Educational medicine information, not personal medical advice.

Kenza Health Hub presents this medicine page as structured health education. Check dose, route, interactions, pregnancy or breast-feeding considerations, and local protocol with a qualified clinician or pharmacist. Read our medical editorial policy.

This guide page is for structured reference only and does not replace a clinician, pharmacist, or emergency review. Dose choice, route choice, interactions, and safety decisions still need professional judgment.

Therapeutic action

Osmotic laxative.

Indications

Prevention of constipation in patients taking opioid analgesics such as codeine and morphine.

Forms and strengths

  • 10 g/15 ml oral solution, to be administered using a measuring device.

Dose and duration

Start lactulose when analgesic treatment continues more than 48 hours.

Lactulose must be taken daily until the end of the opioid treatment. Regular follow up of stool frequency and consistency is essential in order to adjust dosage correctly.

  • Child under 1 year: 5 ml daily (3.3 g daily).
  • Child from 1 to 6 years: 5 to 10 ml daily (3.3 to 6.7 g daily).
  • Child from 7 to 14 years: 10 to 15 ml daily (6.7 to 10 g daily).
  • Child over 14 years and adult: 15 to 45 ml daily (10 to 30 g daily).

Contra-indications, adverse effects, precautions

  • Do not administer to patients with Crohn's disease, ulcerative colitis, intestinal obstruction, or undiagnosed abdominal pain.
  • May cause abdominal discomfort, flatulence, and diarrhoea.
  • In the event of diarrhoea, exclude faecal impaction and intestinal obstruction, then reduce the dose.
  • Pregnancy: no contra-indication.
  • Breast-feeding: no contra-indication.

Source

MSF Essential drugs practical guidelines (January 2026)

This page combines source-derived medicine reference sections with Kenza editorial context, while leaving out the Storage and Remarks sections from the source batch.

Rate this guide

Be the first to rate this guide.